샘플 요청 목록

 카트 문의
시장보고서
상품코드
1773880

세계의 호흡기질환 백신 시장

Respiratory Disease Vaccines
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 475 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

호흡기질환 백신 세계 시장은 2030년까지 954억 달러에 달할 전망

2024년에 917억 달러로 추정되는 호흡기질환 백신 세계 시장은 2024-2030년 분석 기간 동안 CAGR 0.7%로 성장하여 2030년에는 954억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 바이러스 백신은 CAGR 0.6%를 기록하며 분석 기간 종료시에는 600억 달러에 달할 것으로 예측됩니다. 세균 백신 분야의 성장률은 분석 기간 동안 CAGR 0.9%로 추정됩니다.

미국 시장은 250억 달러로 추정, 중국은 CAGR 1.4%로 성장 예측

미국의 호흡기질환 백신 시장은 2024년에 250억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 168억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 1.4%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 0.2%와 0.5%로 예측됩니다. 유럽에서는 독일이 CAGR 0.3%로 성장할 것으로 예측됩니다.

세계 호흡기질환 백신 시장 - 주요 동향 및 촉진요인 정리

호흡기질환 백신에 대한 수요가 급증하는 이유는 무엇일까?

인플루엔자, 폐렴, 결핵, COVID-19와 같은 호흡기 감염증의 유행이 증가함에 따라 호흡기질환 백신에 대한 수요가 급증하고 있습니다. 호흡기질환은 전 세계적으로 이환율과 사망률의 주요 원인이기 때문에 백신 접종 프로그램은 질병 예방 및 공중 보건 관리의 주요 전략이 되고 있습니다. 정부와 의료 기관은 어린이, 노인, 만성질환자 등 취약 계층을 보호하기 위해 대규모 예방접종 캠페인을 실시하고 있습니다. 또한, 전염병의 위협이 증가함에 따라 백신 연구 개발의 중요성이 강화되고, 규제 당국의 승인이 가속화되고, 호흡기 백신 기술 혁신에 대한 자금이 증가하고 있습니다. 전 세계 보건 당국이 예방 의료에 대한 중요성을 강조하면서 호흡기질환 백신 시장은 계속 확대되고 있습니다.

기술 발전이 호흡기 백신 개발을 어떻게 강화하고 있는가?

mRNA 기술, 재조합 단백질 백신, 나노입자 기반 전달 시스템 등 백신 개발의 혁신은 호흡기질환 백신의 생산과 효능에 혁명을 가져왔으며, COVID-19 팬데믹 상황에서 mRNA 백신의 성공은 신속한 백신 개발과 확장성에서 더 많은 혁신의 길을 열었습니다. 또한, 보조제 제형의 발전으로 백신의 면역원성이 개선되어 면역 반응이 더 강하고 오래 지속될 수 있게 되었습니다. 또한 AI를 활용한 예측 모델링과 유전체 시퀀싱은 인플루엔자 및 기타 호흡기 병원체에 대한 백신 균주 선택을 강화하여 매년 백신 접종 프로그램을 최적화하고 있습니다. 이러한 기술의 발전은 생산 주기를 단축하고, 백신의 안정성을 향상시키며, 전 세계적으로 백신의 접근성을 향상시켜 호흡기질환과의 전쟁을 강화할 수 있습니다.

호흡기질환 백신의 확대를 주도하는 시장 동향은 무엇일까?

한 번의 접종으로 여러 호흡기 감염병을 예방할 수 있는 혼합 백신의 채택이 증가하고 있으며, 편의성과 예방접종률 향상으로 인기를 얻고 있습니다. 또한, 보편적 예방접종 프로그램의 확대와 정부 지원 백신 배포 노력도 시장 확대에 기여하고 있습니다. 여행 관련 예방접종의 증가와 고용주가 후원하는 예방접종 프로그램으로 인해 백신에 대한 접근성이 더욱 확대되고 있습니다. 또한, 비강 백신과 마이크로니들 패치 백신을 포함한 비침습적 백신 접종에 대한 관심이 증가하고 있으며, 특히 소아 및 노년층에서 환자의 순응도가 향상되고 있습니다. 백신 기술이 계속 발전함에 따라 새로운 호흡기 병원체를 표적으로 하는 새로운 제형이 개발되고 있어 시장의 장기적인 지속성을 보장하고 있습니다.

호흡기질환 백신 시장의 주요 성장 촉진요인은?

세계 호흡기질환 백신 시장의 성장 동력은 세계 질병 부담 증가, 백신 기술 발전, 예방 접종 프로그램에 대한 정부 및 민간 부문의 투자 증가, COVID-19 백신의 급속한 개발 및 배포는 백신 혁신을 가속화 할 수있는 잠재력을 보여 주며보다 효율적인 백신 제조 파이프라인의 길을 열었습니다. 백신 제조 파이프라인의 길을 열었습니다. 또한, 소아 및 성인 예방접종 프로그램의 확대와 저소득 지역의 백신 형평성을 촉진하기 위한 노력과 함께 시장 성장에 박차를 가하고 있습니다. 백신 연구에 AI와 빅데이터 분석의 통합은 균주 모니터링과 발병 예측을 강화하여 적극적인 백신 개발을 지원하고 있습니다. 전 세계 의료 시스템이 호흡기질환 예방에 우선순위를 두면서 호흡기 백신 시장은 지속적으로 성장할 것으로 예상되며, 감염병 관리의 미래를 형성할 것입니다.

부문

유형(바이러스 백신, 세균 백신, 혼합 백신), 연령층(소아, 성인), 감염증(COVID-19,인플루엔자, 호흡기세포융합바이러스, 폐렴, 기타), 판매 채널(병원·소매 약국, 정부 관련, 기타)

조사 대상 기업 사례

  • Altimmune, Inc.
  • Arcturus Therapeutics
  • AstraZeneca plc
  • Bavarian Nordic
  • Bharat Biotech
  • BioNTech SE
  • CanSino Biologics Inc.
  • Clover Biopharmaceuticals
  • CSL Limited
  • CureVac AG
  • Dynavax Technologies Corporation
  • GeoVax Labs, Inc.
  • GlaxoSmithKline plc(GSK)
  • iBio, Inc.
  • ImmunityBio, Inc.
  • Inovio Pharmaceuticals
  • Johnson & Johnson
  • Medicago Inc.
  • Meissa Vaccines
  • Merck & Co., Inc.

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가가 선별한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm

Global Respiratory Disease Vaccines Market to Reach US$95.4 Billion by 2030

The global market for Respiratory Disease Vaccines estimated at US$91.7 Billion in the year 2024, is expected to reach US$95.4 Billion by 2030, growing at a CAGR of 0.7% over the analysis period 2024-2030. Viral Vaccine, one of the segments analyzed in the report, is expected to record a 0.6% CAGR and reach US$60.0 Billion by the end of the analysis period. Growth in the Bacterial Vaccine segment is estimated at 0.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$25.0 Billion While China is Forecast to Grow at 1.4% CAGR

The Respiratory Disease Vaccines market in the U.S. is estimated at US$25.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$16.8 Billion by the year 2030 trailing a CAGR of 1.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.2% and 0.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.3% CAGR.

Global Respiratory Disease Vaccine Market - Key Trends & Drivers Summarized

Why Is the Demand for Respiratory Disease Vaccines Growing Rapidly?

The demand for respiratory disease vaccines has surged due to the increasing prevalence of respiratory infections such as influenza, pneumonia, tuberculosis, and COVID-19. With respiratory diseases being a leading cause of morbidity and mortality worldwide, vaccination programs have become a primary strategy for disease prevention and public health management. Governments and healthcare organizations are implementing large-scale immunization campaigns to protect vulnerable populations, including children, the elderly, and individuals with chronic conditions. Additionally, the rise of pandemic threats has reinforced the importance of vaccine research and development, leading to accelerated regulatory approvals and increased funding for respiratory vaccine innovations. As global health authorities emphasize preventive healthcare, the market for respiratory disease vaccines continues to expand.

How Are Technological Advancements Enhancing Respiratory Vaccine Development?

Breakthroughs in vaccine development, including mRNA technology, recombinant protein vaccines, and nanoparticle-based delivery systems, have revolutionized the production and efficacy of respiratory disease vaccines. The success of mRNA vaccines during the COVID-19 pandemic has paved the way for further innovations in rapid vaccine development and scalability. Additionally, advancements in adjuvant formulations have improved vaccine immunogenicity, ensuring stronger and longer-lasting immune responses. AI-driven predictive modeling and genomic sequencing have also enhanced vaccine strain selection for influenza and other respiratory pathogens, optimizing annual vaccination programs. These technological advancements are enabling faster production cycles, better vaccine stability, and improved global accessibility, strengthening the fight against respiratory diseases.

What Market Trends Are Driving the Expansion of Respiratory Disease Vaccines?

The increasing adoption of combination vaccines, which protect against multiple respiratory infections in a single dose, has gained popularity due to convenience and improved immunization coverage. Additionally, the expansion of universal immunization programs and government-funded vaccine distribution initiatives has contributed to market growth. The rise of travel-related vaccinations and employer-sponsored immunization programs has further expanded vaccine accessibility. Additionally, the growing focus on needle-free vaccine delivery, including intranasal and microneedle patch vaccines, is enhancing patient compliance, particularly among pediatric and geriatric populations. As vaccine technology continues to evolve, new formulations targeting emerging respiratory pathogens are being developed, ensuring long-term market sustainability.

What Are the Key Growth Drivers of the Respiratory Disease Vaccine Market?

The growth in the global respiratory disease vaccine market is driven by rising global disease burdens, advancements in vaccine technology, and increased government and private sector investments in immunization programs. The rapid development and deployment of COVID-19 vaccines have demonstrated the potential for accelerated vaccine innovation, paving the way for more efficient vaccine production pipelines. Additionally, the expansion of pediatric and adult vaccination programs, coupled with initiatives promoting vaccine equity in low-income regions, is fueling market growth. The integration of AI and big data analytics in vaccine research is also enhancing strain monitoring and outbreak prediction, supporting proactive vaccine development. As global healthcare systems prioritize respiratory disease prevention, the respiratory vaccine market is expected to witness continuous growth, shaping the future of infectious disease management.

SCOPE OF STUDY:

The report analyzes the Respiratory Disease Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Viral Vaccine, Bacterial Vaccine, Combination Vaccine); Age Group (Pediatric, Adult); Infection (COVID-19, Influenza, Respiratory Syncytial Virus, Pneumonia, Others); Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • Altimmune, Inc.
  • Arcturus Therapeutics
  • AstraZeneca plc
  • Bavarian Nordic
  • Bharat Biotech
  • BioNTech SE
  • CanSino Biologics Inc.
  • Clover Biopharmaceuticals
  • CSL Limited
  • CureVac AG
  • Dynavax Technologies Corporation
  • GeoVax Labs, Inc.
  • GlaxoSmithKline plc (GSK)
  • iBio, Inc.
  • ImmunityBio, Inc.
  • Inovio Pharmaceuticals
  • Johnson & Johnson
  • Medicago Inc.
  • Meissa Vaccines
  • Merck & Co., Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Respiratory Disease Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Respiratory Infections Globally Drives Demand for Targeted Vaccine Development
    • Emergence of Novel Pathogens and Virus Variants Throws the Spotlight on Next-Generation Vaccine Platforms
    • Expansion of National Immunization Programs Strengthens Public Sector Procurement of Respiratory Vaccines
    • Increased Global Preparedness for Pandemic Threats Spurs Vaccine R&D and Regulatory Fast-Tracking
    • Technological Advancements in mRNA, Protein Subunit, and Viral Vector Vaccines Propel Platform Diversification
    • Growing Awareness of Vaccine-Preventable Respiratory Illnesses Enhances Routine Adult and Pediatric Immunization
    • Rise in Elderly and Immunocompromised Populations Fuels Demand for Seasonal and Booster Doses
    • Integration of Combination Vaccines and Multivalent Formulations Expands Product Development Opportunities
    • Cold Chain Expansion and Vaccine Logistics Infrastructure Improve Access in Emerging Markets
    • Public-Private Partnerships for Pandemic Preparedness Sustain Investment in Respiratory Vaccine Pipelines
    • Adoption of Adjuvants and Delivery System Innovations Enhances Immunogenicity and Dose Sparing
    • Regulatory Approvals for Intranasal and Mucosal Delivery Systems Drive Innovation in Vaccine Formats
    • Increased R&D in Universal Influenza and Coronavirus Vaccines Targets Broad-Spectrum Protection
    • Integration of Digital Vaccination Records and Travel Health Passes Fuels Compliance and Uptake
    • Government Funding and Global Alliance Support Accelerate Phase 1 to 3 Clinical Trial Timelines
    • Use of AI and Genomic Surveillance in Vaccine Design Enhances Speed and Specificity
    • Growing Focus on One Health Strategies Expands Respiratory Vaccine Applications Across Zoonotic Interfaces
    • Expansion of Pediatric Respiratory Vaccine Schedules Boosts Long-Term Market Stability
    • Rise of CMO/CDMO Capabilities for Respiratory Vaccines Enables Rapid Scale-Up and Outsourcing
    • Consumer Confidence in Post-COVID Immunization Drives Broader Acceptance of Preventive Respiratory Vaccines
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Respiratory Disease Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Respiratory Disease Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Respiratory Disease Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Viral Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Viral Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Viral Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Bacterial Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Bacterial Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Bacterial Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Combination Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Combination Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Combination Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Infections by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Infections by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for COVID-19 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for COVID-19 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for COVID-19 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Influenza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Influenza by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Influenza by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Respiratory Syncytial Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Respiratory Syncytial Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Respiratory Syncytial Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Pneumonia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Pneumonia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Pneumonia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hospital & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hospital & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Hospital & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Government Suppliers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Government Suppliers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Government Suppliers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Pediatric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Pediatric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Pediatric by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Adult by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Respiratory Disease Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • JAPAN
    • Respiratory Disease Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • CHINA
    • Respiratory Disease Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 80: China Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • EUROPE
    • Respiratory Disease Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Respiratory Disease Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Respiratory Disease Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • FRANCE
    • Respiratory Disease Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 107: France Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: France 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: France 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: France 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • GERMANY
    • Respiratory Disease Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Germany 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Germany 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Germany 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Italy 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Italy 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Italy 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Respiratory Disease Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 143: UK Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: UK Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: UK 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 146: UK Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: UK 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: UK 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: UK 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 155: Spain Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Spain Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Spain 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Spain Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Spain 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 161: Spain Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Spain Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Spain 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 164: Spain Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Spain Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Spain 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 167: Russia Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Russia Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Russia 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Russia Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Russia 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 173: Russia Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Russia Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Russia 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 176: Russia Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Russia Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Russia 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Europe Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Europe 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Europe 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Europe 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Europe Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Europe 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Respiratory Disease Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Respiratory Disease Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Asia-Pacific 15-Year Perspective for Respiratory Disease Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Asia-Pacific 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Asia-Pacific Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Asia-Pacific 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Respiratory Disease Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 206: Australia Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Australia Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Australia 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Australia Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Australia 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 212: Australia Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Australia Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Australia 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 215: Australia Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Australia Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Australia 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • INDIA
    • Respiratory Disease Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 218: India Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: India Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: India 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 221: India Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: India Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: India 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 224: India Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: India Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: India 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 227: India Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: India Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: India 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 230: South Korea Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: South Korea Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: South Korea 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: South Korea Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: South Korea 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: South Korea Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: South Korea 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 239: South Korea Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: South Korea Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: South Korea 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Asia-Pacific Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Asia-Pacific Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Respiratory Disease Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 255: Latin America Historic Review for Respiratory Disease Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Latin America 15-Year Perspective for Respiratory Disease Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Latin America 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Latin America 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Latin America 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 266: Latin America Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Latin America Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Latin America 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 269: Argentina Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Argentina Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Argentina 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Argentina Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Argentina 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Argentina Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Argentina 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 278: Argentina Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Argentina Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Argentina 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 281: Brazil Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Brazil Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Brazil 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Brazil Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Brazil 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Brazil Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Brazil 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 290: Brazil Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Brazil Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Brazil 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 293: Mexico Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Mexico Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Mexico 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Mexico Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Mexico 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Mexico Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Mexico 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 302: Mexico Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Mexico Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Mexico 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Latin America Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Latin America 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Latin America 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Rest of Latin America 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Rest of Latin America Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Rest of Latin America 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Respiratory Disease Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 318: Middle East Historic Review for Respiratory Disease Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Middle East 15-Year Perspective for Respiratory Disease Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Middle East 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Middle East 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Middle East 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 329: Middle East Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Middle East Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Middle East 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 332: Iran Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Iran Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 334: Iran 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Iran Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 337: Iran 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 338: Iran Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Iran Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 340: Iran 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 341: Iran Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Iran Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 343: Iran 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 344: Israel Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Israel Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 346: Israel 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Israel Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 349: Israel 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 350: Israel Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Israel Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 352: Israel 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 353: Israel Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Israel Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 355: Israel 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Saudi Arabia Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 358: Saudi Arabia 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 361: Saudi Arabia 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 364: Saudi Arabia 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Saudi Arabia Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 367: Saudi Arabia 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 368: UAE Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: UAE Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 370: UAE 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: UAE Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 373: UAE 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 374: UAE Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: UAE Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 376: UAE 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 377: UAE Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: UAE Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 379: UAE 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Middle East Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 382: Rest of Middle East 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 385: Rest of Middle East 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 388: Rest of Middle East 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Rest of Middle East Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 391: Rest of Middle East 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
  • AFRICA
    • Respiratory Disease Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 392: Africa Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Africa Historic Review for Respiratory Disease Vaccines by Type - Viral Vaccine, Bacterial Vaccine and Combination Vaccine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 394: Africa 15-Year Perspective for Respiratory Disease Vaccines by Type - Percentage Breakdown of Value Sales for Viral Vaccine, Bacterial Vaccine and Combination Vaccine for the Years 2015, 2025 & 2030
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Africa Historic Review for Respiratory Disease Vaccines by Infection - Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 397: Africa 15-Year Perspective for Respiratory Disease Vaccines by Infection - Percentage Breakdown of Value Sales for Other Infections, COVID-19, Influenza, Respiratory Syncytial Virus and Pneumonia for the Years 2015, 2025 & 2030
    • TABLE 398: Africa Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Africa Historic Review for Respiratory Disease Vaccines by Distribution Channel - Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 400: Africa 15-Year Perspective for Respiratory Disease Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Retail Pharmacies, Government Suppliers and Other Distribution Channels for the Years 2015, 2025 & 2030
    • TABLE 401: Africa Recent Past, Current & Future Analysis for Respiratory Disease Vaccines by Age Group - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Africa Historic Review for Respiratory Disease Vaccines by Age Group - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 403: Africa 15-Year Perspective for Respiratory Disease Vaccines by Age Group - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제